Capital raised by Ernexa Therapeutics
1 Form D filing · first filed Mar 2025 · Cambridge, MA
Sr. Vice President of Finance
Signatory on Ernexa Therapeutics's Form D filings · $7.2M raised across 1
Sandra Gurrola is on file as Sr. Vice President of Finance at Ernexa Therapeutics in Cambridge, MA. Ernexa Therapeutics has 1 Form D filing on record, $7.2M raised in total. Sandra Gurrola appears as a signatory on the company's filings.
ERNA-101 is a cell therapy product in development for the treatment of ovarian cancer. It leverages the natural tumor-homing abilities of iMSCs to deliver pro-inflammatory cytokines like IL-7 and IL-15 directly to the tumor microenvironment, enhancing the immune system's ability to target and destroy cancer cells.
